@article{3dc220d88e0e43c78945ffb27d0dfb54,
title = "The effect of systemic chemotherapy on survival in patients with localized, regional, or metastatic adenocarcinoma of the urinary bladder: American Journal of Clinical Oncology: Cancer Clinical Trials",
abstract = "Objectives:To test the effect of systemic chemotherapy on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB).Materials and Methods:Within the Surveillance, Epidemiology, and End Results registry (2004 to 2016), we identified patients with localized (T2-3N0M0), regional (T4N0M0/TanyN1-3M0), and metastatic (TanyNanyM1) ADKUB. Temporal trends, Kaplan-Meier plots, and multivariable Cox regression models were used before and after 1:1 propensity score matching and inverse probability of treatment weighting.Results:Of 1537 patients with ADKUB, 834 (54.0%), 363 (23.5%), and 340 (22.5%) harbored localized, regional, and metastatic disease, respectively. The rates of chemotherapy use increased in localized (estimated annual percentage change [EAPC]: +2.7%; P=0.03) and regional ADKUB (EAPC: +2.4%; P=0.04). Conversely, chemotherapy rates remained stable in metastatic patients (EAPC: +1.6%; P=0.4). In multivariable Cox regression models, chemotherapy use was associated with lower CSM in metastatic ADKUB (hazard ratio [HR]: 0.5; P=0.003), but not in either localized (HR: 0.8; P=0.2) or in regional ADKUB (HR: 1.0; P=0.9). In metastatic ADKUB, the benefit of chemotherapy on CSM persisted after 1:1 propensity score matching (HR: 0.6; P=0.002) and after inverse probability of treatment weighting (HR: 0.4; P",
keywords = "adenocarcinoma, bladder cancer, chemotherapy, inverse probability of treatment weighting adjustment, propensity score, antineoplastic agent, adult, aged, Article, bladder carcinoma, bladder metastasis, cancer chemotherapy, cancer epidemiology, cancer localization, cancer mortality, cancer patient, cancer registry, cancer staging, cancer survival, controlled study, disease surveillance, female, human, human tissue, major clinical study, male, bladder tumor, middle aged, mortality, pathology, retrospective study, survival rate, very elderly, Adenocarcinoma, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Urinary Bladder Neoplasms",
author = "S. Luzzago and C. Palumbo and G. Rosiello and A. Pecoraro and M. Deuker and F.A. Mistretta and Z. Tian and G. Musi and E. Montanari and S.F. Shariat and F. Saad and A. Briganti and {De Cobelli}, O. and P.I. Karakiewicz",
note = "Cited By :1 Export Date: 4 March 2021 CODEN: AJCOD Correspondence Address: Luzzago, S.; Department of Urology, Via Giuseppe Ripamonti, 435, Italy; email: stefanoluzzago@gmail.com References: Moschini, M., D'Andrea, D., Korn, S., Characteristics andclinical significance of histological variants of bladder cancer (2017) Nat Rev Urol., 14, pp. 651-668; Baumeister, P., Zamboni, S., Mattei, A., Histological variants in nonmuscle invasive bladder cancer (2019) Transl Androl Urol., 8, pp. 34-38; Manunta, A., Vincendeau, S., Kiriakou, G., Non-transitional cell bladder carcinomas (2005) Bju Int., 95, pp. 497-502; Vetterlein, M.W., Seisen, T., Leow, J.J., Effect of nonurothelial histologic variants on the outcomes of radical cystectomy for nonmetastatic muscle-invasive urinary bladder cancer (2018) Clin Genitourin Cancer., 16, pp. e129-e139; Lughezzani, G., Sun, M., Jeldres, C., Adenocarcinoma versus urothelial carcinoma of the urinary bladder: Comparison between pathologic stage at radical cystectomy and cancer-specific mortality (2010) Urology., 75, pp. 376-381; Zaffuto, E., Gazdovich, S., Leyh-Bannurah, S.R., Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA (2017) J Urol., 24, pp. 117-123; Witjes, J.A., Lebret, T., Comp{\'e}rat, E.M., Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer (2017) Eur Urol., 71, pp. 462-475; Flaig, T.W., Spiess, P.E., Agarwal, N., Nccn guidelines insights: Bladder cancer, version 5.2018 (2018) J Natl Compr Cancer Netw., 16, pp. 1041-1053; Galsky, M.D., Iasonos, A., Mironov, S., Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract (2007) Urology., 69, pp. 255-259; Hong, J.Y., Choi, M.K., Uhm, J.E., Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract (2009) Med Oncol., 26, pp. 186-192; De Santis, M., Bachner, M., New developments in first-and secondline chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder (2007) Curr Opin Urol., 17, pp. 363-368; Vetterlein, M.W., Wankowicz, S.A.M., Seisen, T., Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology (2017) Cancer., 123, pp. 4346-4355; Berg, S., D'Andrea, D., Vetterlein, M.W., Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? (2019) Cancer., 125, pp. 1449-1458; Logothetis, C.J., Dexeus, F.H., Chong, C., Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: The M.D Anderson experience (1989) J Urol., 141, pp. 33-37; Noone, A.M., Howlader, N., Krapcho, M., (2018) Cancer Statistics Review, 1975-2015-SEER Statistics, , Bethesda, MD: National Cancer Institute; Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies (2011) Multivariate Behav Res., 46, pp. 399-424; Luzzago, S., Palumbo, C., Rosiello, G., Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder (2020) World J Urol.; Wright, J.L., Porter, M.P., Li, C.I., Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder (2006) Cancer., 107, pp. 721-728; Dutta, R., Abdelhalim, A., Martin, J.W., Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis (2016) Urol Oncol Semin Orig Investig., 34, pp. 531e1-531e6; Collazo-Lorduy, A., Castillo-Martin, M., Wang, L., Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition (2016) Eur Urol., 70, pp. 771-775; Siefker-Radtke, A.O., Gee, J., Shen, Y., Multimodality management of urachal carcinoma: The M.D Anderson Cancer Center experience (2003) J Urol., 169, pp. 1295-1298; Seisen, T., Sun, M., Leow, J.J., Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: A propensity score-weighted analysis from the National Cancer Data Base (2019) J Clin Oncol., 34, p. 29; Moschini, M., Xylinas, E., Zamboni, S., Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: Analysis of an international, multicenter, multidisciplinary database (2020) Eur Urol Oncol., 3, pp. 94-101; Luzzago, S., Palumbo, C., Rosiello, G., The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder (2019) J Surg Oncol., 120, pp. 1266-1275",
year = "2020",
doi = "10.1097/COC.0000000000000704",
language = "English",
volume = "43",
pages = "567--574",
journal = "Am. J. Clin. Oncol. Cancer Clin. Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "8",
}